Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients

Huygh, G.; Clement, Paul M. J.; Dumez, H.; Schöffski, P.; Wildiers, H.; Selleslach, J.; Jimeno, J. M.; De Wever, I.; Sciot, R.; Duck, L.; Van Oosterom, A. T.

doi:https://doi.org/10.1155/SRCM/2006/56282

Sarcoma

On this page

Abstract References Copyright Related Articles

Clinical Study | Open Access

Volume 2006 | Article ID 056282 | https://doi.org/10.1155/SRCM/2006/56282

Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients

G. Huygh,¹Paul M. J. Clement,¹H. Dumez,¹P. Schöffski,¹H. Wildiers,¹J. Selleslach,¹J. M. Jimeno,²I. De Wever,¹R. Sciot,¹L. Duck,³and A. T. Van Oosterom¹

Received20 Jul 2005

Revised24 Jul 2006

Accepted19 Oct 2006

Published22 Jan 2007

Abstract

Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tissue and bone sarcoma. Patients or subjects. Eighty-nine patients received ET-743 as a 24-hour continuous infusion at a dose of 900–1500 μg/m2 every 3 weeks. Results. We observed one complete remission, 5 partial remissions, one minimal response, and 16 patients with a disease stabilization of 6 months or more. The objective response rate was 6.7% and the clinical benefit rate at 3 and 6 months was 37.7% and 23.4%, respectively. Responses were noted in patients with lipo-, leiomyo-, osteo-, and myogenic sarcoma, with a median duration of 9.85 months. Toxicity mainly involved an asymptomatic elevation of transaminases and neutropenia. Estimated 1- and 2-year survival rates were 39.4% and 15.8%. Median overall survival was 8.25 months. Discussion. This retrospective analysis confirms that ET-743 induces objective responses and progression arrest in a clinically relevant proportion of patients.

References

R T Greenlee, T Murray, S Bolden, and P A Wingo, “Cancer statistics, 2000,” CA: A Cancer Journal for Clinicians, vol. 50, no. 1, pp. 7–33, 2000.
View at: Google Scholar
P WT Pisters, D HY Leung, J Woodruff, W Shi, and M F Brennan, “Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities,” Journal of Clinical Oncology, vol. 14, no. 5, pp. 1679–1689, 1996.
View at: Google Scholar
A I Spira and D S Ettinger, “The use of chemotherapy in soft-tissue sarcomas,” Oncologist, vol. 7, no. 4, pp. 348–359, 2002.
View at: Publisher Site | Google Scholar
A T Van Oosterom, H T Mouridsen, O S Nielsen et al., “Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients,” European Journal of Cancer, vol. 38, no. 18, pp. 2397–2406, 2002.
View at: Publisher Site | Google Scholar
A Yovine, M Riofrio, J Y Blay et al., “Phase II study of Ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients,” Journal of Clinical Oncology, vol. 22, no. 5, pp. 890–899, 2004.
View at: Publisher Site | Google Scholar
M Van Glabbeke, A T Van Oosterom, J W Oosterhuis et al., “Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline- containing first-line regimens—a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study,” Journal of Clinical Oncology, vol. 17, no. 1, pp. 150–157, 1999.
View at: Google Scholar
J-Y Blay, M van Glabbeke, J Verweij et al., “Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy,” European Journal of Cancer, vol. 39, no. 1, pp. 64–69, 2003.
View at: Publisher Site | Google Scholar
Y Guan, R Sakai, K L Rinehart, and A H-J Wang, “Molecular and crystal structures of Ecteinascidins: potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata,” Journal of Biomolecular Structure and Dynamics, vol. 10, no. 5, pp. 793–818, 1993.
View at: Google Scholar
M Zewail-Foote and L H Hurley, “Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove,” Journal of Medicinal Chemistry, vol. 42, no. 14, pp. 2493–2497, 1999.
View at: Publisher Site | Google Scholar
Y Pommier, G Kohlhagen, C Bailly, M Waring, A Mazumder, and K W Kohn, “DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by Ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata,” Biochemistry, vol. 35, no. 41, pp. 13303–13309, 1996.
View at: Publisher Site | Google Scholar
S Jin, B Gorfajn, G Faircloth, and K W Scotto, “Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 12, pp. 6775–6779, 2000.
View at: Publisher Site | Google Scholar
M Minuzzo, S Marchini, M Broggini, G Faircloth, M D'Incalci, and R Mantovani, “Interference of transcriptional activation by the antineoplastic drug Ecteinascidin-743,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 12, pp. 6780–6784, 2000.
View at: Publisher Site | Google Scholar
Y Takebayashi, P Pourquier, D B Zimonjic et al., “Antiproliferative activity of Ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair,” Nature Medicine, vol. 7, no. 8, pp. 961–966, 2001.
View at: Publisher Site | Google Scholar
W W Li, N Takahashi, S Jhanwar et al., “Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of Ecteinascidin-743 as a potent cytotoxic agent,” Clinical Cancer Research, vol. 7, no. 9, pp. 2908–2911, 2001.
View at: Google Scholar
C Gajate, F An, and F Mollinedo, “Differential cytostatic and apoptotic effects of Ecteinascidin-743 in cancer cells: transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis,” Journal of Biological Chemistry, vol. 277, no. 44, pp. 41580–41589, 2002.
View at: Publisher Site | Google Scholar
K L Rinehart, G Faircloth, and J Fernandez Puentes, “Ecteinascidins: a family of marine derived compounds with antineoplastic activity,” Annals of Oncology, vol. 5, no. suppl 8, P931, p. 185, 1994.
View at: Google Scholar
H R Hendriks, H H Fiebig, R Giavazzi, S P Langdon, J M Jimeno, and G T Faircloth, “High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer,” Annals of Oncology, vol. 10, no. 10, pp. 1233–1240, 1999.
View at: Publisher Site | Google Scholar
E Izbicka, R Lawrence, E Raymond et al., “In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients,” Annals of Oncology, vol. 9, no. 9, pp. 981–987, 1998.
View at: Publisher Site | Google Scholar
G Valoti, M I Nicoletti, A Pellegrino et al., “Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts,” Clinical Cancer Research, vol. 4, no. 8, pp. 1977–1983, 1998.
View at: Google Scholar
M A Villalona-Calero, S G Eckhardt, G Weiss et al., “A phase I and pharmacokinetic study of Ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies,” Clinical Cancer Research, vol. 8, no. 1, pp. 75–85, 2002.
View at: Google Scholar
S Delaloge, A Yovine, A Taamma et al., “Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients—preliminary evidence of activity,” Journal of Clinical Oncology, vol. 19, no. 5, pp. 1248–1255, 2001.
View at: Google Scholar
A Taamma, J L Misset, M Riofrio et al., “Phase I and pharmacokinetic study of Ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors,” Journal of Clinical Oncology, vol. 19, no. 5, pp. 1256–1265, 2001.
View at: Google Scholar
D P Ryan, J G Supko, J P Eder et al., “Phase I and pharmacokinetic study of Ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies,” Clinical Cancer Research, vol. 7, no. 2, pp. 231–242, 2001.
View at: Google Scholar
C van Kesteren, C Twelves, A Bowman et al., “Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study,” Anti-Cancer Drugs, vol. 13, no. 4, pp. 381–393, 2002.
View at: Publisher Site | Google Scholar
V HC Bramwell, H T Mouridsen, A Santoro et al., “Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas,” European Journal of Cancer and Clinical Oncology, vol. 23, no. 3, pp. 311–321, 1987.
View at: Publisher Site | Google Scholar
J Verweij, H T Mouridsn, O S Nielssen et al., “The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view,” Critical Reviews in Oncology/Hematology, vol. 20, no. 3, pp. 193–201, 1995.
View at: Publisher Site | Google Scholar
O S Nielsen, I Judson, Q van Hoesel et al., “Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group,” European Journal of Cancer, vol. 36, no. 1, pp. 61–67, 2000.
View at: Publisher Site | Google Scholar
W P Steward, J Verweij, R Somers et al., “Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group,” Journal of Clinical Oncology, vol. 11, no. 1, pp. 15–21, 1993.
View at: Google Scholar
S R Patel, S Vadhan-Raj, N Papadopolous et al., “High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies—dose-response and schedule dependence,” Journal of Clinical Oncology, vol. 15, no. 6, pp. 2378–2384, 1997.
View at: Google Scholar
K H Antman, L Ryan, A Elias, D Sherman, and H E Grier, “Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma,” Journal of Clinical Oncology, vol. 7, no. 1, pp. 126–131, 1989.
View at: Google Scholar
R Palumbo, S Palmeri, M Antimi et al., “Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas,” Annals of Oncology, vol. 8, no. 11, pp. 1159–1162, 1997.
View at: Publisher Site | Google Scholar
A Le Cesne, I Judson, D Crowther et al., “Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus infosfamide plus recombinant human granulocyte-macrophage colony- stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group,” Journal of Clinical Oncology, vol. 18, no. 14, pp. 2676–2684, 2000.
View at: Google Scholar
R Garcia-Carbonero, J G Supko, J Manola et al., “Phase II and pharmacokinetic study of Ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy,” Journal of Clinical Oncology, vol. 22, no. 8, pp. 1480–1490, 2004.
View at: Publisher Site | Google Scholar
A Ruiz-Casado, J Lopez-Martin, and A Nieto, “Ecteinascidin in heavily pretreated advanced sarcoma patients as a compassionate basis,” Proceedings of the American Society for Clinical Oncology, vol. 21, p. 408a, 2002.
View at: Google Scholar
W S Ferguson and A M Goorin, “Current treatment of osteosarcoma,” Cancer Investigation, vol. 19, no. 3, pp. 292–315, 2001.
View at: Publisher Site | Google Scholar
A Le Cesne, J Y Blay, I Judson et al., “Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial,” Journal of Clinical Oncology, vol. 23, no. 3, pp. 576–584, 2005.
View at: Publisher Site | Google Scholar
M Van Glabbeke, J Verweij, I Judson, and O S Nielsen, “Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas,” European Journal of Cancer, vol. 38, no. 4, pp. 543–549, 2002.
View at: Publisher Site | Google Scholar
G Demetri, J Manola, and D Harmon, “Ecteinascidin-743 (ET-743) induces durable responses and promising 1-year survival rates in soft tissue sarcomas (STS): final results of phase II and pharmakinetic studies in the USA,” Proceedings of the American Society for Clinical Oncology, vol. 20, p. 352a, 2000.
View at: Google Scholar
C Laverdiere, A Kolb, and P Meyers, “Phase II study of ET-743 in recurrent osteosarcoma,” Proceedings of the American Society for Clinical Oncology, vol. 21, p. 96a, 2002.
View at: Google Scholar
J Gomez, L Lopez Lazaro, C Guzman et al., “Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743,” Proceedings of the American Society for Clinical Oncology, vol. 19, p. 187a, 2000.
View at: Google Scholar

Copyright

Copyright © 2006 G. Huygh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

393

Downloads

875

Citations